A CE technical file and an ASEAN Common Submission Dossier Template (CSDT) are not the same document. They share underlying science but differ in structure, required annexes, and language obligations. Thai FDA screens for CSDT format compliance before review begins. A submission that does not meet format requirements does not advance to expert review regardless of the quality of the underlying technical data.
Thailand's device submission format follows the ASEAN Common Submission Dossier Template (CSDT), the harmonized submission structure used across ASEAN member states under the ASEAN Medical Device Directive (AMDD). The CSDT is the Thai FDA-accepted format for Class 2, 3, and 4 device submissions. Class 1 listing submissions use a simplified document set; the full CSDT applies to notification and license pathway applications.
Technical documentation within the CSDT may be submitted in English. Application forms and Instructions for Use (IFU) for home-use devices must be in Thai. The Thai-language obligation applies to specific documents within the dossier, not to the entire technical file. Manufacturers with existing CE or FDA documentation can submit much of the underlying technical content in English, provided the CSDT structure, headings, and required annexes are met.
The distinction between having the data and having it in the correct CSDT structure is where most reformatted CE submissions fail. Thai FDA does not identify which sections are missing or incorrectly structured and invite the applicant to revise; a non-compliant submission is rejected at screening and must be resubmitted in full.
The CSDT is organized into defined sections. Each section has specific content requirements. The following represents the core components of a Class 2, 3, or 4 CSDT submission under Thai FDA requirements.
Application form (Thai language for home-use devices), Letter of Authorization from the foreign manufacturer, establishment license of the Thai local holder, and ISO 13485 certificate (Classes 2, 3, and 4). These documents must be current at submission. An expired establishment license or ISO 13485 certificate blocks the application from proceeding.
A complete description of the device: physical characteristics, components, accessories, variants, and the stated intended use as it will be labeled for the Thai market. The intended use in the Thai submission governs the classification determination and the clinical evidence standard. It must be consistent with the LOA and with the approved labeling.
Manufacturing process overview, quality control procedures, and evidence of design controls consistent with ISO 13485. The manufacturing information in the CSDT is not a full manufacturing dossier; it is a structured summary sufficient to support the classification and the clinical evidence sections.
Risk management documentation in accordance with ISO 14971. The risk management file must address risks specific to the device's intended use in Thailand, not only risks identified in the home-market submission. Thai FDA's expert review assesses whether the risk management approach is appropriate for the device class and the clinical context.
Clinical and performance data supporting the device's safety and performance for the stated intended use. The clinical evidence standard varies by device class. For lower-risk Class 2 devices, literature-based justification and equivalence arguments are generally accepted. For Class 3 and 4 devices, clinical investigation data or robust post-market clinical follow-up data is expected. CE clinical evaluation reports and FDA clinical data are accepted as supporting evidence; they do not substitute for Thai FDA's own clinical evidence assessment.
Draft labeling and Instructions for Use consistent with the B.E. 2568 (2025) labeling regulation, in force from June 20, 2026. Home-use device labels and IFU must be in Thai. Professional-use device labels and IFU may be in Thai or English. The labeling submitted in the CSDT is the labeling Thai FDA approves; post-approval labeling changes require a variation submission.
CE marking under EU MDR and US FDA 510(k) clearance are accepted as supporting evidence in CSDT submissions to Thai FDA. They carry evidentiary weight: they demonstrate that the device has been assessed by a recognized regulatory authority against defined safety and performance standards. They are meaningful inputs to the MDCD's expert review.
They are not substitutes for Thai FDA registration. CE marking does not confer market authorization in Thailand. 510(k) clearance does not. Neither approval shortens the expert review requirement, reduces the CSDT documentation burden, or replaces the classification determination under Thai AMDD criteria. A device that holds CE marking and 510(k) clearance still requires a complete CSDT dossier, a Thai local holder, an establishment license, and a Letter of Authorization.
The practical value of CE and 510(k) documentation in a Thai submission is in the clinical evidence section: a CE clinical evaluation report or an FDA-reviewed clinical dataset provides a structured foundation for the CSDT clinical evidence component. The CE technical file structure itself does not map to CSDT sections and cannot be submitted as-is.
As of May 1, 2026, Thailand and Malaysia operate a bilateral medical device reliance program. Under this program, devices already approved by Malaysia's Medical Device Authority (MDA) may bypass the external expert evaluation step at Thai FDA when submitted with a full CSDT dossier.
The program applies to Classes 2, 3, and 4 under Thai FDA classification (equivalent to MDA Classes B, C, and D). Class 1 devices are excluded. The applicant must hold a current, valid MDA approval and submit a complete CSDT dossier to the MDCD; the reliance applies specifically to the external expert evaluation step, not to the entire review process.
The program was established following a confidentiality agreement signed on December 4, 2025 at the 29th GHWP Annual Meeting in Bangkok, preceded by a pilot program running from February 1 to April 30, 2026. It is currently the only confirmed bilateral reliance pathway between Thai FDA and another major regulatory authority for medical devices. No equivalent program exists with the US FDA, the EU, or other ASEAN markets as of the date of this content.
For manufacturers with an existing Malaysian MDA approval, this program represents a meaningful reduction in the Thai expert review burden. For manufacturers without MDA approval, the program is not directly applicable; CE marking and 510(k) clearance remain supporting evidence only, not reliance triggers.
Thai FDA device registration is not a one-time submission. Approved registrations carry ongoing compliance obligations that fall on the Thai local license holder and, through the holder, on the foreign manufacturer. These obligations begin from the date of registration approval and continue for the lifecycle of the product on the Thai market.
Device registrations require periodic renewal. The renewal application window falls within a defined period before registration expiration. Renewal for Group 1 devices (CSDT pathway) is processed on payment; Group 2 renewals require supporting documentation. All post-approval change notifications must be resolved before a renewal application is submitted. The specific renewal window and documentation requirements should be confirmed with current Thai FDA guidance or your local holder before the renewal period approaches.
Any change to an approved device that affects labeling, intended use, design, materials, manufacturing process, or other approved specifications requires a variation submission to the MDCD before the change is implemented in the Thai market. Changes implemented without prior MDCD approval are a compliance violation under the Medical Device Act.
The Thai local license holder is responsible for reporting adverse events involving the registered device to Thai FDA. Reporting obligations are tiered by the severity and nature of the event. Thailand participates in the ASEAN harmonized post-market surveillance information exchange framework, adopted at the 12th ASEAN Medical Device Committee meeting in September 2023, based on the IMDRF National Competent Authority Report (NCAR) format. Specific reporting timelines and form requirements should be confirmed directly with the MDCD or your local holder.
Discontinuation of a registered device must be reported to Thai FDA. The reporting obligation falls on the Thai local license holder. Discontinuation without notification is a compliance failure under the Medical Device Act.
We prepare CSDT dossiers to Thai FDA format requirements, not to CE technical file structure. Before assembly begins, we conduct a gap analysis between the manufacturer's existing documentation and what the MDCD requires in each CSDT section. Gaps identified before filing are documentation work. Gaps identified after a rejection are timeline loss.
For manufacturers with existing MDA approval, we assess eligibility for the Thailand-Malaysia bilateral reliance pathway and structure the CSDT submission accordingly. For manufacturers without MDA approval, we identify which existing international documentation can serve as supporting evidence and what additional work is required to meet Thai FDA's clinical evidence expectations for the relevant device class.
Post-approval compliance is managed as part of our ongoing license holder service. Renewal, variations, and adverse event reporting obligations do not fall through the gap between registration approval and the next interaction with Thai FDA.